|
Total: $25.75M Year to Date: $382.78M |
|||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Details (Date) |
Algeta ASA (Norway; OSLO:ALGETA) |
Bayer Schering Pharma AG (Germany) |
€5 ($6.4) |
For signed manufacturing and supply agreements for future commercial sale of Alpharadin to treat bone metastases (7/23) |
Amira Pharmaceuticals Inc.* |
GlaxoSmithKline plc (UK) |
ND |
For the successful progression of an Amira-discovered 5-lipoxygenase-activating protein inhibitor into Phase II development in patients with asthma (7/20) |
Cipher Pharmaceuticals Inc. (Canada; TSX:DND) |
Kowa Pharmaceuticals America Inc. |
$1 |
For reaching a cumulative sales milestone for its fenofibrate product Lipofen (7/8) |
Cleveland BioLabs Inc. (CBLI) |
Biomedical Advanced Research and Development Authority |
$4.1 |
For exercising an option regarding the development of Protectan; it supports the manufacturing process of the compound and three additional registration batches of the drug, plus additional animal studies (7/30) |
Curis Inc. (CRIS) |
Debiopharm SA (Switzerland) |
$3 |
For the start of a Phase I trial of Debio 0932, a small-molecule heat shock protein 90 inhibitor being tested for advanced solid tumors or lymphoma (7/7) |
Isis Pharmaceuticals Inc. (ISIS) |
GlaxoSmithKline plc (UK) |
$5 |
Related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease; Isis will develop the drug to Phase II proof of concept, at which time GSK has the option to license it (7/30) |
MorphoSys AG (Germany; FSE:MOR) |
Novartis AG (Switzerland) |
ND |
For the start of a Phase I trial testing a HuCAL-derived fully human antibody for musculoskeletal diseases (7/2) |
Optimer Pharmaceuticals Inc. (OPTR) |
Cempra Pharmaceuticals Inc. |
$0.5 |
As a result of the continuing development of CEM-101, a macrolide under investigation as a treatment of respiratory infections (7/9) |
Perseid Therapeutics LLC (subsidiary of Maxygen Inc.; MAXY) |
Astellas Pharma Inc. (Japan) |
$5 |
As part of a collaboration to co-develop and commercialize CTLA4-lg therapeutics (7/8) |
XOMA Ltd. (XOMA) |
AVEO Pharmaceuticals Inc. |
$0.75 |
For the start of a Phase II trial to evaluate its AV-299 antibody for the treatment of non-small-cell lung cancer (7/27) |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; * Private company. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. ** Denotes the date the item ran in BioWorld International. FSE = Frankfurt Stock Exchange; TSX = Toronto Stock Exchange. |
